Every 8-K that GeneDx Holdings Corp. (WGS) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow WGS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full WGS filings page.
GeneDx Holdings Corp. reported second quarter 2026 revenue of $114.4 million, up 11% year-over-year, with exome and genome test revenue of $100.3 million, up 17%. Exome and genome volume rose 32% to 30,785 tests, reflecting strong demand across geneticists, pediatric neurology and NICU.
Profitability remained mixed. The company generated adjusted gross margin of about 70% and adjusted net income of $0.4 million, but recorded a GAAP net loss of $17.7 million for the quarter and a net loss of $81.056 million for the first half of 2026. GAAP gross margin was 68%.
Cash, cash equivalents, marketable securities and restricted cash totaled $133.5 million as of June 30, 2026. GeneDx amended and restated its loan agreement with Blackstone, adding a $50.0 million term loan facility that raises total facility capacity to $150.0 million and is paired with a $5.0 million equity investment, resulting in a pro forma cash position of approximately $188 million. Management reaffirmed full-year 2026 guidance, including revenue of $475–$490 million, at least 30% exome and genome volume growth, approximately 70% adjusted gross margin and positive adjusted net income, and guided Q3 2026 revenue to $122–$124 million with adjusted net income of about $2 million.
GeneDx Holdings Corp. reported the results of its Annual Meeting of Stockholders held on June 18, 2026. Stockholders elected Class II director Katherine Stueland to a three-year term, with 18,325,894 votes for and 5,893,466 votes withheld, and 3,409,327 broker non-votes.
Stockholders ratified Ernst & Young LLP as independent registered public accounting firm for the year ending December 31, 2026, with 27,466,639 votes for, 158,884 against and 3,164 abstentions. They also approved, on an advisory basis, the compensation of named executive officers, with 22,705,946 votes for and 1,471,593 against.
In an advisory vote on how often to hold future say-on-pay votes, 23,816,121 votes favored an annual vote, 24,246 favored every two years, 358,017 favored every three years, and 20,976 abstained. There were 29,675,547 Class A shares outstanding on the April 20, 2026 record date.
GeneDx Holdings Corp. appointed Mark Gardner as President, effective June 15, 2026. He will oversee the company’s lab and commercial operations, report to CEO Katherine Stueland, and join the executive leadership team, while Bryan Dechairo shifts to a role leading product, technology and innovation initiatives.
Gardner previously led molecular genomics and oncology at Quest Diagnostics and held senior roles at Corza Medical, OmniSeq and Thermo Fisher Scientific. His employment agreement includes a $530,000 annual base salary, a target annual bonus equal to 65% of base salary, and $2,000,000 in restricted stock units vesting over four years, along with severance and change‑in‑control protections.
GeneDx Holdings Corp. reported first quarter 2026 revenue of $102.3 million, up 17% year-over-year, driven by strong demand for exome and genome testing. Exome and genome revenue rose to $90.6 million, a 27% increase, on 34% higher test volumes of 27,488.
Profitability weakened: GAAP net loss widened to $63.3 million, and adjusted net results shifted to an $8.2 million adjusted net loss from adjusted net income of $9.2 million a year earlier, despite an adjusted gross margin of 69%. The company ended March 31, 2026 with $171.7 million in cash, cash equivalents, marketable securities and restricted cash.
GeneDx cut its full‑year 2026 revenue guidance to $475–$490 million from $540–$555 million, while still targeting at least 30% growth in exome and genome volume, at least 20% growth in exome and genome revenue, approximately 70% adjusted gross margin, and positive adjusted net income for the year. Second quarter 2026 guidance calls for revenue of $110–$112 million, exome and genome revenue of about $100 million, roughly 30,000 exome and genome tests, approximately 70% adjusted gross margin, and an adjusted net loss of about $5 million.
GeneDx Holdings Corp. entered into a new Loan Agreement with Blackstone-affiliated lenders providing a $100.0 million term loan funded at closing. The company used the proceeds to repay its prior term loan and plans to direct remaining funds toward balance sheet initiatives, potential reductions of certain operating obligations, and general corporate purposes.
The Term Loan bears interest at Term SOFR plus 4.50%, with a 1.50% SOFR floor, and matures five years from the closing date. It is secured by a first lien on substantially all assets of GeneDx and its guarantor subsidiaries and includes a minimum liquidity covenant of $50 million, mandatory prepayments upon specified events, and optional prepayment subject to yield protection premiums.
GeneDx Holdings Corp. reported strong growth for 2025, with revenue rising to $427.5 million, up 41% year over year, and exome and genome test revenue reaching $360.3 million, up 54%. Adjusted gross margin improved to 71% and adjusted net income increased to $41.8 million from $9.4 million in 2024, while GAAP net loss narrowed to $21.0 million.
Fourth-quarter 2025 revenue was $121.0 million, including $104.0 million from exome and genome testing, with test volumes up 34.3% to 27,761. The company ended the year with $172.3 million in cash, cash equivalents, marketable securities and restricted cash and reaffirmed 2026 guidance for revenue of $540–$555 million, 33–35% exome and genome growth, adjusted gross margin of at least 70%, and positive adjusted net income.
GeneDx Holdings Corp. filed a report stating that it issued a press release on January 12, 2026 outlining its expectations for preliminary, unaudited revenue for the fourth quarter and full year 2025. The update also covers exome and genome test result volumes, GAAP and adjusted gross margin for the same periods, and levels of cash, cash equivalents, marketable securities and restricted cash as of December 31, 2025.
The company additionally provided full year 2026 guidance and released an investor presentation prepared for the 44th Annual J.P. Morgan Healthcare Conference. These materials are furnished as exhibits and are not deemed filed for liability purposes under the securities laws or automatically incorporated into other regulatory documents.
GeneDx Holdings Corp. furnished an 8-K announcing it issued a press release and will hold a conference call to discuss financial results for the quarter ended September 30, 2025.
The company attached its Press Release and an Earnings Presentation as Exhibits 99.1 and 99.2. The materials are furnished under Item 2.02 and are not deemed “filed” under Section 18 of the Exchange Act or incorporated by reference, except as specifically stated.
GeneDx Holdings Corp. reported that its Board of Directors appointed Thomas Fuchs, Dr.sc. as a Class I director, effective September 17, 2025. His term will run until the company’s 2028 Annual Meeting of Stockholders, and the Board size increased from seven to eight directors with this appointment.
Dr. Fuchs is the SVP and Chief AI Officer at Eli Lilly and Company, where he leads artificial intelligence initiatives across drug discovery, clinical trials, manufacturing, commercial activities, and internal functions. He has previously held senior academic and research roles in AI and computational pathology and founded several companies, including Paige AI.
Under GeneDx’s Non-Employee Director Compensation Policy, Dr. Fuchs will receive an initial restricted stock unit grant valued at $420,000, vesting over three years, subject to his continued service. The company also plans to enter into its standard form indemnity agreement with him, and there are no related-party transactions requiring disclosure in connection with his appointment.
GeneDx Holdings Corp. (Nasdaq: WGS) filed a Form 8-K to report the results of its 18 June 2025 Annual Meeting of Stockholders.
Director elections: Stockholders elected Class I directors for terms expiring in 2028. Eli D. Casdin received 16,013,641 votes for and 6,823,343 withheld, while Joshua Ruch received 17,211,360 votes for and 5,625,624 withheld; 2,682,501 broker non-votes applied to both nominees.
Auditor ratification: Ernst & Young LLP was reappointed as independent registered public accounting firm for fiscal 2025 with 25,459,253 votes for, 49,423 against and 10,809 abstentions—roughly 99% support.
All agenda items passed. The near-unanimous auditor vote signals confidence in financial oversight, yet the 25-30% withholding against the directors highlights moderate shareholder dissent that the board may need to address. No other material business, financial results or strategic actions were disclosed.